Chief Medical Officer
Cassandra Choe-Juliak has been in the oncology industry for 16+ years, both in Medical Affairs and in clinical drug development. At Karyopharm, Dr. Choe-Juliak served as the Head of Development for the multiple myeloma and sarcoma programs where she led the development program for selinexor, a first-in-class XPO inhibitor that was approved via accelerated approval. She was most recently the Head of Clinical Development at Affimed GmbH where she was responsible for all of the clinical stage innate (NK-) cell bispecific engagers including leading AFM13 from Phase 1 to a registration-directed program and developing first-in-human monotherapy and combination trials for AFM24 in EGFR-associated cancers.
Dr. Choe-Juliak received her B.A. from Georgetown University and a M.S. in Pharmacology/Toxicology along with her M.D. from Medical College of Virginia.